DocGo Inc. (DCGO) Earnings Call Transcript & Summary

November 10, 2025

NASDAQ US Health Care Health Care Providers and Services earnings 44 min

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thank you, Operator. Before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions might be used to flag such forward-looking statements; these forward-looking statements don't guarantee future performance, and we can't promise you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to significant risks, uncertainties, and assumptions, a great many of which lie outside our control and which might lead our actual results or outcomes, or when results or outcomes occur, to differ materially from what our forward-looking statements contain. These risks, uncertainties, and assumptions include, though they aren't limited to, the ones covered in risk factors and other sections of DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, our earnings release for this quarter, and additional reports and statements DocGo has filed with the SEC, which we direct your attention to. Actual outcomes and results, or when results or outcomes occur, might differ materially from what these forward-looking statements express or imply. Beyond that, today's call mentions non-GAAP financial measures. Reconciliations of these non-GAAP financial measures against the most directly comparable GAAP financial measures appear in our earnings release within the current report on Form 8-K that contains our earnings release, which is available on our website, docgo.com, and also filed with the SEC. What's shared on this call is accurate only as of the date discussed. Investors shouldn't presume that statements will stay relevant and operative at a later point. We take on no obligation to update anything discussed on this call to reflect events or circumstances following the date of this call, or to reflect new information or the occurrence of unanticipated events, except to whatever extent the law requires. At this point, I'm pleased to hand the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.

Lee Bienstock

executive
#2

Thank you, Mike, and thanks to everyone for being with us today. For DocGo, 2025 has represented a significant year of transition, and before getting into greater detail about how we performed, I'd like to open this call with four main headlines from the quarter. To begin with, we saw record volumes during the quarter across every one of our base business offerings. The approach we've taken to create a sturdy, evergreen healthcare business is now bearing fruit. Next, our balance sheet remains solid, and we plan to deploy that cash toward funding growth and seizing the opportunities ahead of us. Third, we couldn't be more enthusiastic about bringing SteadyMD into the fold, since its virtual care network spanning 50 states and a roster of more than 500 advanced practice providers will let us scale with greater efficiency. Earlier today, we issued 2026 guidance calling for revenue of $280 million-$300 million alongside a full year 2026 Adjusted EBITDA loss of $15 million-$25 million, and we expect the bulk of that Adjusted EBITDA loss to land in the first half of the year. Our 2026 revenue guidance works out to 12%-20% year-over-year base business growth. Should any acquisitions happen or new contracts be won, those would come on top of that figure, and we'd update our 2026 guidance whenever necessary. If we hit the upper end of our 2026 revenue guidance range, we'd anticipate finishing the year at a positive Adjusted EBITDA run rate; our vision is a bold one, building a company that delivers the capabilities of a doctor's office right into a patient's living room. I'm thrilled about the investment we're making to build these capabilities, which to my mind is a modest price for the promise of something carrying transformational potential, for our company and for our industry alike. Before walking through each business vertical, let me stress that all of our service lines, apart from our care gap closure and primary care offerings, are Adjusted EBITDA positive on a contribution basis. I believe it's worth pointing this out, since corporate overhead costs at our present scale, together with the investment we're making in the capabilities I just mentioned, can obscure their value. Now let me address our medical transportation and payer-provider mobile health verticals. Record volumes arrived in Q3 for our flagship medical transportation business, powered by many long-term contracts offering strong visibility and an enviable customer roster that includes Jefferson Health, Mount Sinai Health System, New York City Health + Hospitals, HCA Healthcare TriStar, the NHS in the U.K., and others. We anticipate this business will produce more than $200 million of revenue in 2025, which makes it a strong foundational asset. As we bring on additional scale and ramp staffing in this segment across the coming two to three years, we expect to be able to push the Adjusted EBITDA contribution margin even higher, to roughly 12%. Demand for our services remains incredibly strong, and we see opportunities to grow revenue within our existing customer base. A number of our major health system clients rely on our end-to-end transportation offering, and that includes software we own, ambulances we dedicate, EMS crews, plus personnel who handle their transfer center operations. Through our Epic Integrated Technology platform, we deliver efficiency and transparency while establishing one authoritative record for managing transportation across multiple vendors. When operating in that role, we frequently can decide between dispatching one of our own ambulances or going with another transportation provider in cases where no staffed unit of ours is free to take the trip; our estimate is that during the past 12 months, more than 26,000 trips went to outside companies, and many of those could have been handled by our own fleet had we possessed the available service-level capacity. We've stepped up efforts to bring in talent and intend to add hundreds more EMS personnel as soon as doing so makes sense, so we can build that capacity and more fully capture this built-in demand from clients we already serve. We anticipate that these focused new hires will let us secure millions of dollars in extra top-line revenue on contracts we already hold in 2026; put simply, our transportation segment addresses an essential market need, turns a profit on its own, and stands as a valuable foundational asset. Turning now to our payer and provider vertical, which we expect will produce roughly $50 million in revenue during 2025, including about $5 million contributed by the SteadyMD acquisition in mid-October, and should climb to $85 million in the coming year. Services in this vertical span care gap closure, primary and preventative care, telehealth, remote patient monitoring, mobile phlebotomy, and additional payer and provider offerings. A key piece of what we provide in this vertical is our remote patient monitoring operation, which has advanced significantly over the past year. Remote patient monitoring runs at an annual rate of about $15 million, with an Adjusted EBITDA contribution margin above 10%, and that figure should keep rising through 2026. We've inked 13 new contracts or expansions during this year thanks to robust demand, and we have eight more proposals either submitted or working through contracting. We're eager to continue building out this capability in a field where high multiples are the norm. One part of our payer and provider vertical that is ramping more slowly than we'd hoped yet remains very promising is our primary care services; originally we had budgeted somewhere around $5 million-$10 million in primary care revenue for 2025. Progress is visible here, and we just obtained a sizable list from a major health plan to extend these services to 10,000 members, set to launch in Q4 and scale up in early 2026; additionally, within our payer and provider vertical, our care gap closure and transitions of care business grew by more than four times comparing Q3 2025- Q3 2024. Even though we put a lot of money into product development, training, and technology during 2025 to strengthen what we can do, we anticipate that pace of spending will drop a great deal in 2026, and that should help us move toward our objective of reaching profitability. As we push to bring our care gap and primary care business into the black as quickly as we can, I'd like to emphasize the reasons behind this strategic outlay to develop these capabilities. DocGo's capacity to use a clinical workforce powered by technology to connect with hard-to-reach groups living with chronic conditions provides real worth to the payers and providers we serve. What we offer helps individuals stay healthier and remain in their own residences, and it could meaningfully reduce costs across health systems. Given how rising expenses, reimbursement that stays flat, overcrowded facilities, and persistent operational difficulties are converging in healthcare right now, we think DocGo's proposition is set up to generate considerable value and stands as a major opportunity for us. Although this payer and provider side of the business requires a long time to build out, we've achieved substantial progress across the past two years, and we see strong potential for growth in it. As I mentioned during our previous earnings call, we already serve 2 of the top 10 national payers and are holding active talks with both of those customers about growing those agreements.

Lee Bienstock

executive
#3

On top of that, we're currently working through contracts with 2 additional members of the 10 largest national payers, and another 10 proposals are sitting in our business development pipeline. To show what these ties could mean, I'd like to walk through how one of our bigger payer clients has grown over the years. Back in 2023, our initial year of work with a large California health plan, we completed 789 patient visits in total. During 2024, that figure climbed by almost 65%, hitting 1,293. Come 2025, it should rise by another 250%, arriving at 4,500, and in 2026, another 280% increase is anticipated, pushing it past 17,000 visits, all based on plans already in place. That same client began with just 1 transition to care program, then layered on care gap closure, and more recently brought in longitudinal care services too. So in short, these relationships take time to build momentum, yet they can speed up fast once customers recognize the value we bring. As I noted, we also broadened our capabilities substantially by acquiring virtual care provider SteadyMD last month. We feel we secured a highly favorable deal for shareholders, given how we put this transaction together and what it delivers. If you weren't able to join our webcast last month, it's available on our investor relations website, SteadyMD brings a 50-state virtual clinician workforce, clinical operations, and top-tier technology that enables real-time matching of patient needs with clinical expertise. This company delivers virtual care to leading consumer healthcare and digital wellness brands, among them 2 Fortune 10 customers. SteadyMD keeps a roster exceeding 500 clinicians, should serve more than 3 million patients in 2025, and is forecast to bring in roughly $25 million of revenue this year. SteadyMD's broad virtual provider network should let DocGo deliver patient care more efficiently by eventually connecting DocGo's mobile health clinicians in the field with SteadyMD's clinical network. We're excited about this acquisition for many reasons. First, it hands us a 50-state virtual care footprint, greatly widening our clinical capacity and putting us in position to grow our offering to payers as well as providers. Second, we've believed for a long time that combining our last-mile clinical delivery strengths with virtual care could unleash the power and promise of telehealth, forming an ideal end-to-end solution. We're eager for the possible synergies this unlocks, and we'll aim to both expand what we already offer and possibly roll out new services next year. Finally, we see major opportunities for cross-pollinization between the standout customer bases DocGo and SteadyMD have each assembled, and we're keen to pursue those too. We still hold the view that DocGo possesses a rare knack for buying traditional healthcare assets where we can layer on our technology, mobile health capabilities, and wide customer base to generate further value. A lot of healthcare organizations out there view DocGo's last-mile healthcare delivery capabilities as the piece they've been missing, which makes us a highly appealing partner, and we intend to stay active when it comes to M&A. All told, 2025 has been a year of transition as we shifted past emergency response contracts and put more and more emphasis on carrying out DocGo's evolution into a provider of long-term, integrated, technology-driven healthcare solutions that serve what our customers need today and tomorrow. I feel immense pride in the progress we're making, since we're positioned for strong growth across each of our key verticals. We anticipate that the investment in our early-stage business lines will gradually taper off throughout 2026. We completed a strategic acquisition in SteadyMD that widens our footprint, brings in accretive capabilities, and adds a roster of blue-chip customers we can keep building upon. On top of that, we keep expanding our pipeline of new business and seek out potential acquisition opportunities, and both of these can help us gain critical mass, achieve profitability, and create additional shareholder value in the years ahead. Our future is bright and valuable; we possess the right products and services to address critical needs in our healthcare industry, have built differentiated technology and capabilities, and have business lines such as medical transportation and remote patient monitoring that are already firmly EBITDA positive, and we have the balance sheet to make our vision of bringing the doctor's office to the living room a reality. At this point, I'll turn things over to Norm to cover the financials. Norm, please go ahead.

Norm Rosenberg

executive
#4

Thanks, Lee, and good afternoon, everyone. For the third quarter of 2025, total revenue came in at $70.8 million, versus $138.7 million during the same quarter in 2024. That decline in revenue year-over-year stemmed completely from migrant-related projects reaching their sunset. If you set aside revenue from migrant-related programs, revenue rose 8%, reaching $62.4 million in Q3 of 2025, up from $58 million in Q3 of 2024. Medical transportation services revenue grew to $50.1 million in Q3 of 2025, compared with $48 million in transport revenues recorded during the third quarter of 2024. Gains across nearly every one of our U.S. markets pushed revenues higher, and some of the strongest growth came in Texas and Tennessee. Mobile health revenue during the third quarter of 2025 totaled $20.7 million, a drop from $90.7 million in the third quarter of last year, as migrant services wound down. Roughly $8 million of migrant-related revenues were included in this year's figure. Non-migrant mobile health revenues climbed by over 20% year-over-year, fueled by growth in care gap closures, remote patient monitoring, and mobile phlebotomy. Adjusted EBITDA for the third quarter of 2025 showed a loss of $7.1 million, against Adjusted EBITDA of $17.9 million in the third quarter of 2024. Adjusted gross margin — which strips out depreciation and amortization along with several one-off items, and is the margin measure we monitor most closely — stood at 33% in the third quarter of 2025, versus 36% in the third quarter of 2024. In the third quarter of 2025, adjusted gross margins for the medical transportation segment reached 31.7%, compared with 30.7% in Q3 of 2024, marking the highest gross margins this segment has delivered since Q1 of 2024. Our transportation business operated at the highest utilization rates we have ever seen during the third quarter. With those utilization rates in mind, expanding our field labor team will be critical, and we would expect that to drive higher revenues and better gross margins for transport in 2026. Mobile health segment adjusted gross margin was 36.2%, versus 38.8% in the third quarter of 2024, though it improved from adjusted gross margins of 32.5% in the second quarter of 2025. We anticipate continuing to replace migrant-related revenues with service lines carrying relatively higher margins, such as remote patient monitoring and mobile phlebotomy. We keep making significant investments in our care gap closure business, both on a cost of goods sold basis and an operating cost basis. We estimate that mobile health's adjusted gross margin would have exceeded 40% in Q3 of 2025 if you exclude the care gap closure business. Some non-recurring items also had a sizable effect on our gap results this quarter, so I want to walk through them briefly. In the cost of goods sold area, we took on higher insurance costs of about $5.2 million. A big chunk of that was extra premium we owed for workers' comp coverage going back to 2022 and 2023. The main drivers there were a bigger employee base tied to the migrant program, plus settling a sizable auto insurance claim from an incident in 2022 in the California transport market, which we've since exited. On top of that, inside operating expense we took non-cash charges from writing down a number of intangible assets and goodwill; for the quarter those charges came to $16.7 million. In Q3 we kept making headway on shoring up the balance sheet, clearing what we owed on our line of credit and taking $30 million of debt off the books. We kept working down those older, bigger invoices, and that let us bring in roughly $1.7 million of operating cash flow in the quarter even with the operating losses we posted. Across the first nine months of 2025, cash flow from operations has come to almost $45 million. At September 30, 2025, cash and cash equivalents in total, counting restricted cash and investments, stood at $95.2 million, which is lower than the $107.3 million we had when the year started. That said, since we cleared the full outstanding balance on our credit line in Q3, our cash net of debt sits comfortably above where our net position was at the start of this year. For the first time since late 2023, our balance sheet carries no debt. Accounts receivable kept coming down as well, especially the migrant-related receivables. When the quarter closed, we had roughly $37 million of AR from the different migrant programs, a bit over 1/3 of total company AR. For comparison, migrant program-related AR was $54 million when Q2 ended, $120 million when Q1 ended, and $150 million when 2024 ended, which back then was about 71% of the company total. From the start of those programs through today, we've collected roughly 96% of all migrant-related receivables, and we're still confident we'll collect every remaining outstanding amount. With our cash balance improved and the credit line debt retired, we're in a strong position to get the company through this transitionary period that's still underway. Over the last seven weeks or so of 2025, our sharpest focus will be on collecting what's left of the migrant-related receivables. If those amounts come in during Q4, then after adjusting for the SteadyMD acquisition, we'd expect year-end cash balances to be above where they were when Q3 ended. We expect to finish 2026 with about $65 million of cash, which we see as the low point, subject of course to buybacks or any further acquisitions. And finally, with 2025 now in its home stretch, we want to walk through our full-year outlook and give a preliminary view on 2026. For the full year 2025, our expectation now is revenues between $315 million and $320 million. Roughly $68 million to $70 million of that total is tied to migrant-related projects, meaning base revenue ought to land near $250 million. On the Adjusted EBITDA side, our projection for the whole of 2025 is a loss somewhere in the $25 million to $28 million band. Turning to 2026, we're looking at revenue between $280 million and $300 million, a gain of 12%-20% measured against 2025's base revenue, alongside an anticipated Adjusted EBITDA loss for the full year of between $15 million and $25 million. That said, if we hit the upper bound of that 2026 revenue range, we'd anticipate finishing the year running at a positive Adjusted EBITDA rate. Sequentially across 2026, our expectation is that revenue climbs and EBITDA results get better in each of the year's four quarters. With that, I'd like to hand the call back to the operator so we can take questions and answers. Operator, please go ahead. Thank you.

Pito Chickering

analyst
#5

Hi there, good afternoon. I appreciate you taking my question. If we look at the margins that are implied for Q4, they seem to be roughly — I believe it comes out to 13%. Could you walk us through a bridge, compared with the margin from Q3, which was down 10%? How much of that came from SteadyMD acquisition services core ops, just bridging 3Q to 4Q margins?

Norm Rosenberg

executive
#6

In Q3, there was nothing related to SteadyMD. SteadyMD appeared in October, so you're going to have the bulk of the quarter from SteadyMD. We believe that figure ought to be approximately $5 million and a bit, a bit above $5 million in revenue during the quarter, and I'd describe it as slightly EBITDA negative for that time frame. It truly shouldn't have a material impact. It will affect the margin percentage, but apart from that it won't have much of an effect. We will have lower, we will have essentially no revenue from, or a very small revenue figure from the migrant-related revenue, so that too is going to affect the margin somewhat. Okay.

Pito Chickering

analyst
#7

And regarding the 2026 EBITDA guidance, the margins implied for next year sit at 10%, but we're finishing the fourth quarter around a negative 13% margin. Could you take us through how that gets better across the year, and what should we be putting into our models for EBITDA in the first half compared with the back half?

Norm Rosenberg

executive
#8

Yes, absolutely. We see a couple of places where our model suggests we'll perform somewhat better. To start with, looking at gross margin percentage, it's worth noting that the Q3 adjusted gross margin, as we discussed, came in at roughly 33%; that figure is above what we posted in Q1 or Q2 of this year, and we view it as something like a proxy for where we're headed over the next few quarters. We have certain projects, particularly on the transport side, that ought to lift the gross margin somewhat, though in all practicality, their bigger effect will likely land in the second, third, and fourth quarter of next year rather than in the fourth quarter of 2025 or the first quarter of 2026. There's a bit of upside in that area too. When it comes to operating expense, we keep pushing hard to bring our SG&A down, and since we managed to remove a couple of million dollars per quarter in SG&A, that ought to contribute as well toward the back half of next year. There is a scale. Our expectation, Pito, is that whatever revenue we see in Q1 will mark the low point of 2026. It'll rise, and it'll rise in the way our model lays out into Q2, into Q3, into Q4, and as a result, the EBITDA loss or profitability will get better each quarter as we move through Q1, Q2, Q3, and Q4. We believe that will be the effect. Turning to your second question, on the breakdown, I'd say the majority of the expected negative EBITDA figure will arrive in the first half of the year; it's clearly going to be weighted toward the first half of the year when it comes to those losses, and after that you get a far smaller loss in the third quarter, and possibly even, we think, a positive figure in the fourth quarter.

Pito Chickering

analyst
#9

Okay, and the final thing I want to ask about is the revenue outlook for 2026 — what amount are you factoring in for migrants in the coming year, and how should transport be modeled compared with mobile health in that period?

Lee Bienstock

executive
#10

Thanks, and absolutely, Pito — Lee here. Regarding revenues tied to migrants in 2026, our expectation is none, meaning the figure for next year will be 0. As for how the guide splits out, it's worth keeping in mind that what we're giving is current guidance built off the baseline of the business as it stands today. Should there be any fresh contract wins or M&A, those would come on top of what we're putting out this evening. The split runs roughly two-thirds transport and one-third mobile health; that's basically how you should think about it.

Pito Chickering

analyst
#11

Great. Thanks so much.

Lee Bienstock

executive
#12

Of course.

Sarah James

analyst
#13

Thanks. I'd like to explore payer-provider revenue growth a bit further. Clearly, there's a really robust pipeline on your end. When you move up from $50 million in 2025 to $85 million in 2026, is it correct to annualize SteadyMD's contribution at $15 million of that, leaving $20 million coming from organic growth? What deal closure assumptions are baked in for that pipeline you mentioned, whether through possibly expanding your existing two national payers or bringing in two others?

Lee Bienstock

executive
#14

Sure thing, Sarah. Appreciate you asking. To start, the $85 million for payer and provider next year includes roughly $25 million tied to the SteadyMD acquisition. That reflects the run rate the business currently carries. Naturally, since we announced that acquisition a few weeks back, integration is underway. So $25 million out of the $85 million comes as SteadyMD's contribution for next year, with the rest being $60 million from our existing payer and provider baseline business. On your specific question, I'm happy you raised it. No deal closures, extra M&A, or pipeline contribution is factored in; what we're considering is the contracts we hold today. We're considering the geographies where we operate today, the patient list handed to us thus far, and our present customer set, and building next year's guidance on that basis, for both payer and provider as well as the transportation segments of the business. Great.

Sarah James

analyst
#15

Could you give us some color on how these payer-provider agreements evolve as they move from transition of care into care gap closure and then into longitudinal care? How large is the revenue opportunity, in orders of magnitude, and how might that shift the margin profile for that segment?

Lee Bienstock

executive
#16

Of course. Like you said, Sarah, the majority of our contracts with payers and providers generally begin with care gap closure work, in which the payer hands us a roster of members who have unresolved gaps and haven't been seen. That might include diabetic retinal exams, bone density scans, annual wellness visits, vaccinations. We reach out to those members, we connect with them wherever they happen to be, and we assist in resolving those gaps; these are patients with chronic illness; usually they're people who cost the health plans a substantial amount of money. The health plans face strong incentives to ensure they're connecting with these members. If they fail to do so, their plan's quality scores take a hit. Naturally, patients wind up being admitted to the hospital. That runs the payers a great deal of money. They give us rosters of members. These are the members who have unresolved gaps in care, and we will go see them. They begin either with care gap closure or with transitional care management. When a patient is leaving the hospital, having already been admitted or having come through the emergency room, and is heading out, we partner with them to ensure their transition of care into the next setting — which might be their home, or might be a different facility — is handled properly, and that we're tending to the incision site, adjusting medications, and verifying their vitals, so that their transition of care is properly managed and they avoid being readmitted; that's generally where our payer work begins. What we're also discovering is that many of these patients require primary care and preventative care. As I said, we're in the midst of broadening our existing relationships into primary care and preventative care, more longitudinal care. Rather than delivering a care gap closure visit or transitional care, we're delivering long-term care along with preventative care and primary care for that patient. That's usually the second step in that process. You can envision situations where we get those patients set up with remote patient monitoring, as I said. Truly wrapping the patient in the care they require, connecting with them wherever they are, resolving care gaps first, then ensuring they receive appropriate primary and preventative care. That's how these contracts generally progress. The rosters grow bigger, patient needs grow larger and more diverse, and we're positioned to expand into those payer contracts as they witness the real impact of our work and how much better off their patients are thanks to our services. As I mentioned, there's one additional point I'd like to cover here: with many of the health plans we partner with — this is an example I brought up during the prepared remarks — we've assisted them in cutting the ED readmission rate for patients enrolled in that transitional care management program by more than 50%. The payers are experiencing genuine value, and they keep handing us additional work. Our guidance rests on that — the contracts we hold right now and our capacity to grow within our existing customer base. Should any new pipeline additions, M&A activity, or major contract wins come through, those would sit on top of the guidance we're providing tonight.

Sarah James

analyst
#17

Got it. Thank you very much.

Lee Bienstock

executive
#18

Absolutely.

Ryan MacDonald

analyst
#19

Hello, and thank you for allowing me to ask. Perhaps I'll begin with the transportation segment — it's encouraging to learn about the increased utilization rates and how that serves as an indicator for additional spending to grow the workforce. In light of what you're observing, how do you reconcile supply with demand so that, as the team keeps expanding, there's sufficient demand to keep those teams busy in the best possible manner, avoiding any dilution of margins? Appreciate it.

Lee Bienstock

executive
#20

Of course, Ryan, and I appreciate the inquiry. We felt it was worthwhile to share the volume of trips that at present get outsourced or passed along to outside providers; when we examined that figure across the prior 12 months, it totaled roughly 26,000 trips; that is genuinely the figure we treat as the built-in demand contained within the agreements we hold, along with the amount of personnel and capacity required to fulfill it. That's genuinely the figure guiding our approach. Naturally, if we secure new agreements, additional hiring would be necessary, yet that remains the figure guiding our approach. We managed to put a number on those trips throughout every one of our markets, plus the matching staffing level needed to fulfill those trips internally rather than sending them out; our whole hiring strategy is built upon that. Tallying them together — those 26,000 trips spanning all our markets — it appears roughly another 700 to 800 staff members must be brought on. Now, I can share that we've advanced on this during the last several weeks, yet we keep accelerating that effort quite aggressively at the moment. Significant initiatives are underway inside the organization to guarantee that we hold onto the excellent employees already with us while drawing in fresh team members, enabling us to grow those operations. It's fundamentally anchored in the volume of trips we currently send to outside providers, drawn from the built-in demand our agreements provide.

Ryan MacDonald

analyst
#21

That's useful context. Thanks, Lee. As a follow-up, it's clearly encouraging to hear about the ongoing scaling and expansion in remote patient monitoring. There are 13 contracts this year and eight additional proposals. Could you discuss which core areas and care categories you're concentrating on with remote? The reason I'm asking is that, obviously, there's been recent news about United scaling back RPM except, I believe, for chronic heart failure and hypertension during pregnancy. I'm just wondering what you're picking up in the market about whether that produces any knock-on effect for other payers. Thanks.

Lee Bienstock

executive
#22

Yes, Ryan, I'm really glad you brought that up. In fact, our primary offering in remote patient monitoring is centered on the cardiology space. You brought up chronic heart failure, and other insurers reducing coverage to just cardiology and heart disease; that would actually be favorable for us; we possess deep expertise in cardiology and implantable cardiac devices such as loop recorders, pacemakers, and similar products. That is truly our specialty, and that is where we're putting our investment. That is what our remote patient monitoring efforts concentrate on, these devices that transmit data, especially for heart failure and other chronic conditions tied to cardiology. We have been broadening from there into additional specialties such as diabetes and others, but our group's main focus at present is cardiology.

Ryan MacDonald

analyst
#23

Awesome. Appreciate all the color, Lee.

Lee Bienstock

executive
#24

Of course.

Jenny Shen

analyst
#25

Hi, this is Jenny Shen, filling in for David. I appreciate you taking my question. To start, I'd like to hear your take right now on the hospital sector and the overall spending climate there. We've talked with a number of hospital executives, and some told us that uncertainty in the market—things like ACA and Medicaid among them—has made them more careful with their budgets, and they anticipate possible pressure on volumes and spending. Has that kind of sentiment shown up among your customers, or have you heard anything like it? Volumes look solid. Any perspective you can share on how hospital customers feel about spending? Thank you.

Lee Bienstock

executive
#26

Of course, Jenny. Great to hear from you, and that's a terrific question. My sense is that it's still too soon to say what the real effects of any new legislation will be, but you can definitely picture a situation where more Americans lack adequate coverage or any coverage at all, and they wind up in hospitals and emergency rooms, putting real strain on capacity. Naturally, those hospitals may not be able to collect reimbursement from patients who are underinsured or uninsured; that is certainly something we worry about; we invest a great deal of time with hospital executives, and I talk with hospital system CEOs on a very regular basis. I'd say our central focus is figuring out how to cut their costs and drive greater efficiency; that has genuinely been our focus all along. We believe we can assist them in managing patient flow, ensuring patients don't remain an additional night at the hospital when it isn't necessary simply because medical transportation couldn't be arranged. That's something we help with. Our platform was built specifically for that purpose. We believe hospital systems have recently shown us openness to that. And naturally, when it comes to the payer and provider side, our entire aim, once again, whether that's with hospital systems or payers, is to help bring down their costs and their utilization. That transitional care management program I mentioned—when a patient is being discharged, that moment is crucial for engaging the patient; they're on their way out of the hospital; we're frequently right there at the bedside, setting up a follow-up appointment, making certain we will visit them, maybe at their home, to confirm their discharge planning is properly handled; that carries a lot of value, and it will help patients avoid returning to the hospital; it benefits hospitals since they face penalties when patients come back inside a 30-day window. We're helping prevent patients from doing that. It benefits the payers because, once again, patients cost the most while they're in the hospital. Once more, we're genuinely enthusiastic about what we're building here. We believe it's very well timed. We believe it's extremely strategic for the healthcare ecosystem. Truly, everything is built around attempting to save the system money, the hospital's money, and the payer's money, and we believe we'll succeed at that.

Norm Rosenberg

executive
#27

Sure, Jenny — the thing I'd tack onto that is, just from what I've seen and heard, over the past 6 to 12 months, we've been talking with hospital systems — we've been doing ambulance work for a long while — but a few major hospital systems have come up in those talks that, before roughly the last 6 or 12 months, we hadn't truly engaged with, and they're now considering exactly that: handing off to an outside party the job of managing how patients move in and out of their buildings. That was something they'd forever handled internally. It has forever been a source of frustration for them, and at this point they genuinely need to weigh becoming more efficient and removing it from their shoulders; we're seeing chances that I doubt were around even 2 years back.

Jenny Shen

analyst
#28

That sounds great. Just to quickly follow up, has the government shutdown had any kind of impact that you've observed? Did it play any role at all in municipal decisions? Thanks.

Lee Bienstock

executive
#29

Yes, absolutely. In the past few earnings calls, we've talked about how we've put less emphasis on our work in the population government space. Our real focus has been on hospital systems, payers, providers, and that steady customer base. That group is going to get an increasing share of our attention, time, and resources. That's where our main emphasis truly lies. Honestly, I believe it's too soon to say whether any of these legislative or policy shifts have had an effect. So far, we aren't seeing one. Honestly, many of these policy shifts won't take effect until much later — next year, or even the one after that. Our focus is squarely on execution. We believe the value we offer holds up regardless of what the healthcare landscape or policy looks like, or whatever circumstances the healthcare system finds itself in, or whichever policies happen to be active, since our purpose is to reduce costs across the board — for the system itself, for hospital systems, for CMS, and for our insurance partners. That's genuinely what we're aiming for, and we're confident it will stay pertinent and meaningful in any scenario ahead.

Jenny Shen

analyst
#30

That's wonderful. Thanks. Thanks. The final question you have is from Mike Latimore with Northland Capital. Go ahead, please. Hello, Ardit here, speaking for Mike Latimore. Could you shed some light on what bookings looked like during the third quarter and by how much they increased on a sequential basis?

Lee Bienstock

executive
#31

Which business do you mean? On the whole, yes. What I'd say is that nearly every one of our businesses grew sequentially; in transport, take the U.S., for example, and we measure it by how many trips we operated; trip count rose by a mid-single-digit percentage from the prior quarter, and for a quarter-over-quarter figure, that's extremely, extremely strong. That pleases us. Clearly, our payer and provider business lines each posted some growth across the quarter. My sense is that all of those business lines delivered a bigger revenue figure in Q3 than in Q4. Actually, looking ahead to 2026, had we merely taken what Q3 produced and annualized it, that alone would already have placed us in fairly solid shape relative to the guidance we provided. We absolutely experienced an uptick in volumes. I believe we noted in the release or somewhere else that record volumes were achieved. Sure, it didn't hugely surpass our prior records, but across every one of those business lines, Q3 volumes came in above anything we had previously witnessed. Understood. What amount of cash are you anticipating holding when the year closes? Taking the close of Q3 purely as our starting point, we held $95 million counting both cash and restricted cash, or $73 million counting only unrestricted cash. Our expectation is that this figure rises on a net basis by several million dollars, on the assumption that, as we anticipate, we will gather payment on the rest of the sizable migrant-related invoices still outstanding. That ought to be sufficient to absorb any operating loss, and on that foundation we should manage to produce a bit of operating cash flow; we anticipate the figure climbing slightly by the time Q4 ends. As we have conveyed, we believe that from that point the figure begins declining at the close of Q1, at the close of Q2, then rebounds over the latter half of the year; our view is that we would finish 2026 at roughly $65 million or above. Okay. Understood. Thanks. Certainly.

Lee Bienstock

executive
#32

Thank you. And thank you all for joining us today. Be well.

Operator

operator
#33

Everyone, that brings today's conference call to a close; we appreciate your joining us very much. You're welcome to hang up now. Have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.